CLPT Stock Risk & Deep Value Analysis
Clearpoint Neuro Inc
DVR Score
out of 10
What You Need to Know About CLPT Stock
We analyzed Clearpoint Neuro Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CLPT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CLPT Risk Analysis & Red Flags
What Could Go Wrong
The company is deeply unprofitable and burning cash. While current cash reserves provide a runway, prolonged unprofitability or a failure of partner clinical trials could necessitate significant dilutive capital raises, severely impacting shareholder value and pushing out the timeline for achieving profitability.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Persistent negative free cash flow (FY24 -$9.23M, H1 2025 -$9.0M)
- ⚠
Historical significant insider sales by CEO ($713,972 on 10/10/2025) and Director ($132,800 on 6/10/2025) outside the 90-day window
- ⚠
Reliance on successful progression of early-stage neuro gene and cell therapy pipelines for future growth
Upcoming Risk Events
- 📅
Slower-than-expected progress in partner clinical trials
- 📅
Need for additional dilutive capital raises if cash burn accelerates
- 📅
Emergence of a strong competitor with a superior or cheaper delivery platform
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates below 20% year-over-year for two consecutive quarters.
- 🚪
Sell if cash and equivalents fall below $20 million without a clear, non-dilutive funding plan.
- 🚪
Re-evaluate position if a major partner's clinical trial for a gene/cell therapy fails unexpectedly.
Unlock CLPT Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Clearpoint Neuro is a compelling high-risk, high-reward investment positioned to capitalize on the explosive growth of neuro gene and cell therapies. Its proprietary MRI-guided navigation platform, robust IP, and strong strategic partnerships make it an indispensable enabling technology. Despite current unprofitability, the company's scalable model and 'manageable cash burn' are typical for a firm at this stage, prioritizing future market leadership and substantial competitive advantage within a massive total addressable market.
Is CLPT Stock Undervalued?
Unlock the full AI analysis for CLPT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CLPT Price Targets & Strategy
12-Month Target
$25.00
Bull Case
$34.00
Bear Case
$9.00
Valuation Basis
Based on 8x EV/Sales on projected FY2027 revenue of $90 million.
Entry Strategy
Dollar-cost average between $10.00-$12.00, seeking opportunities on dips towards recent support levels or the 50-day SMA.
Exit Strategy
Consider taking initial profits at $25.00-$30.00, with a stop-loss order placed if the stock consistently trades below $9.00.
Portfolio Allocation
7-10% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CLPT Financially Healthy?
Profitability
Gross Margin
61.38%
Operating Margin
-65.36%
Net Margin
-69.08%
Return on Equity
-122.17%
Revenue Growth
17.78%
EPS
$-0.90
Balance Sheet
Current Ratio
5.91
Quick Ratio
4.94
Debt/Equity
1.75
Cash & Equivalents
$45.92M
Other
Beta (Volatility)
1.31
Does CLPT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to the high regulatory hurdles, significant R&D investment required for precision neuro-navigation technology, and the substantial time and cost involved for surgeons and hospitals to adopt and integrate new platforms, creating high switching costs. Its early mover advantage in the gene/cell therapy delivery space also contributes.
Moat Erosion Risks
- •Technological obsolescence if non-invasive or superior delivery methods emerge rapidly
- •Intense competition from larger, well-funded medical device companies entering the niche
- •Challenges to its intellectual property or patent expirations
CLPT Competitive Moat Analysis
Sign up to see competitive advantages
CLPT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. No specific recent social media sentiment data available, but general enthusiasm for high-growth biotech/medtech can exist.
Institutional Sentiment
Neutral. No recent analyst upgrades/downgrades or price target changes were identified. However, the existing high score from prior analysis implies underlying institutional confidence in the long-term thesis.
Insider Activity (Form 4)
Directors Pascal E. R. Girin (755 shares, ~$6,870), Timothy T. Richards (442 shares, ~$4,022), and R. John Fletcher (1,270 shares, ~$11,570) were granted shares as compensation on April 1, 2026. Earlier sales (outside 90 days) include CEO Joseph Burnett selling 26,463 shares ($713,972) on 10/10/2025 and Director Richards selling 10,000 shares ($132,800) on 6/10/2025.
Options Flow
Normal options activity. No specific unusual options flow data was provided in the real-time market intelligence.
Earnings Intelligence
Next Earnings
2026-05-12 (Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Historical earnings reaction patterns are not specified in the provided data, but given its growth stage and unprofitability, significant volatility on earnings news (especially guidance or partnership updates) is common.
Key Metrics to Watch
Competitive Position
Top Competitor
Intuitive Surgical (ISRG) / Medtronic (MDT) in broader neuro-robotics/surgical platforms, though CLPT's niche is more specialized.
Market Share Trend
Gaining market share within its specialized niche (MRI-guided intracranial delivery for gene/cell therapies) as this emerging market expands.
Valuation vs Peers
CLPT likely trades at a premium on EV/Sales compared to more mature, diversified medical device companies due to its higher growth potential and specialized niche in the nascent neuro gene/cell therapy market.
Competitive Advantages
- •Proprietary MRI-guided neuro-navigation platform
- •Strong intellectual property portfolio
- •Established strategic partnerships with leading pharmaceutical/biotech companies
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CLPT Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (May 12, 2026)
- •Updates on partner clinical trial progress (e.g., positive data readouts)
- •Potential new strategic partnerships or platform expansions
Medium-Term (6-18 months)
- •Increased adoption of Clearpoint platform across neurosurgical centers
- •Progression of partnered gene/cell therapies into later-stage trials
- •Expansion of platform capabilities to new indications or geographies
Long-Term (18+ months)
- •Widespread commercialization and adoption of neuro gene/cell therapies using Clearpoint's platform
- •Establishment as the de facto standard for intracranial drug delivery
- •Industry disruption through minimally invasive brain surgery advancements
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CLPT?
- ✓
Acceleration in year-over-year revenue growth rates
- ✓
Consistent improvement in gross margins and progress towards operating leverage
- ✓
Positive clinical trial readouts from partner programs utilizing the Clearpoint platform
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Clearpoint Neuro Inc Makes Money
Clearpoint Neuro develops and commercializes an advanced MRI-guided neuro-navigation platform used primarily for precise delivery of gene and cell therapies into the brain and other difficult-to-reach areas of the central nervous system. They generate revenue by selling their sophisticated hardware systems, providing consumable components that are required for each procedure, and offering technical support and related services to neurosurgeons, hospitals, academic research institutions, and pharmaceutical/biotech companies conducting clinical trials. Their core value proposition lies in enabling highly accurate, minimally invasive, and repeatable delivery of novel neurotherapies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Clearpoint Neuro Inc (CLPT)?
As of April 19, 2026, Clearpoint Neuro Inc has a DVR Score of 9.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Clearpoint Neuro Inc?
Clearpoint Neuro Inc's market capitalization is approximately $349.7M..
What is the risk level for CLPT stock?
Our analysis rates Clearpoint Neuro Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Clearpoint Neuro Inc's revenue growing?
Clearpoint Neuro Inc has reported revenue growth of 17.8%. The company is showing strong top-line momentum.
Is CLPT stock profitable?
Clearpoint Neuro Inc has a profit margin of -69.1%. The company is currently unprofitable.
How often is the CLPT DVR analysis updated?
Our AI-powered analysis of Clearpoint Neuro Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 19, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CLPT (Clearpoint Neuro Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.